Overview

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Telitacicept in patients with IgA nephropathy. The control group will be observed for up to 6months without administration of Telitacicept. This Single center, Randomized, Open Label, Comparative study will evaluate the effect and safety of and Standard treatment for 6months in IgA Nephropathy.

Phase:

PHASE3

Details

Lead Sponsor:

The Affiliated Hospital of Xuzhou Medical University

Treatments:

Adrenal Cortex Hormones
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Methylprednisolone
Prednisolone
telitacicept